Adjuvant Osimertinib vs. Placebo in Completely Resected Stage IA2-IA3 EGFR-Mutated NSCLC: ADAURA2

By sjmartinez • March 6, 2023

Tsutani Y, Goldman JW, Dacic S, Yatabe Y, Majem M, Huang X, Chen A, van der Gronde T, He J. Adjuvant Osimertinib vs. Placebo in Completely Resected Stage IA2-IA3 EGFR-Mutated NSCLC: ADAURA2. Clin Lung Cancer. 2023 Feb 8:S1525-7304(23)00020-7. doi: 10.1016/j.cllc.2023.02.002. Epub ahead of print. PMID: 36872181.

Tags: Adjuvant, Early-stage, Hematology/Oncology, Publications, Resectable, targeted therapy, Tyrosine kinase inhibitor

Author Correction: Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus

Lawrenson K, Kar S, McCue K, Kuchenbaeker K, Michailidou K, Tyrer J, Beesley J, Ramus SJ, Li Q, Delgado MK, Lee JM, Aittomäki K, Andrulis[...]

Pregnancy and breast cancer in young women: current updates and future directions

Zhang S, Guclu SB, Lipsyc-Sharf M, Kapoor NS. Pregnancy and breast cancer in young women: current updates and future directions. Ther Adv Med Oncol. 2025[...]

Fixed-Duration Epcoritamab Plus R2 Drives Favorable Outcomes in Relapsed or Refractory Follicular Lymphoma

Falchi L, Sureda A, Leppä S, Vermaat JS, Nijland M, Christensen JH, de Vos S, Holte H, Merryman RW, Lugtenburg PJ, Abrisqueta P, Linton K,[...]